我在那里看病人 (3)
我的评论
选择研究
-
First-in-Human Phase I Trial of TPST-1120, PPARα的抑制剂, as Monotherapy or in Combination with Nivolumab, in 病人 with Advanced Solid Tumors.
Cancer research communications
-
修正:伊他替尼或Parsaclisib联合派姆单抗治疗晚期实体瘤:一项I期研究.
Cancer research communications
-
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in 病人 with Advanced Malignancies.
临床癌症研究:美国癌症研究协会的官方期刊
Pilot Study of Pancreatic Cancer Screening
Proportion of participants with an abnormal MRI finding will be reported as an event. 在有强烈胰腺癌家族史(FH)的十大赌博靠谱网络平台者中,估计发生率为19%,而在没有st的十大赌博靠谱网络平台者中,发生率为10%...
招聘
Combination Therapy in Cancers With Mutations in DNA Repair Genes
将报告根据NCI不良事件通用术语标准(CTCAE)第5版分类和分级的治疗中出现不良事件的十大赌博靠谱网络平台者的百分比
招聘
4.8